Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Corn

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2013
Targeting fibroblast growth factor pathways in prostate cancerPaul G Corn, Fen Wang, Wallace L McKeehan, et al.
European Urology Focus|December 25, 2017
Taxane-based Combination Therapies for Metastatic Prostate CancerPaul G Corn, Neeraj Agarwal, John Charles Araujo, et al.
Journal of the National Cancer Institute|September 16, 2011
Novel therapies for metastatic castrate-resistant prostate cancerFarshid Dayyani, Gary E Gallick, Christopher J Logothetis, et al.
Future Medicinal Chemistry|December 16, 2011
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancerGary E Gallick, Paul G Corn, Amado J Zurita, et al.
European Urology|July 14, 2019
Prostate Cancer: Quo Vadis?Christopher J Logothetis, Ana Aparicio, Filippos Koinis, et al.
Nature Genetics|October 14, 2003
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau proteinPaul G Corn, E Robert McDonald, James G Herman, et al.
Cancer Biology & Therapy|December 25, 2008
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivityAbujiang Pataer, Stephen G Swisher, Jack A Roth, et al.
Cancer Metastasis Reviews|February 14, 2014
Src signaling pathways in prostate cancerAndreas Varkaris, Anastasia D Katsiampoura, John C Araujo, et al.
Expert Opinion on Investigational Drugs|November 1, 2011
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trialsAndreas Varkaris, Paul G Corn, Sanchaika Gaur, et al.
Current Medicinal Chemistry|December 17, 2016
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future DirectionsSpyridon P Basourakos, Likun Li, Ana M Aparicio, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2013
Targeting fibroblast growth factor pathways in prostate cancerPaul G Corn, Fen Wang, Wallace L McKeehan, et al.
European Urology Focus|December 25, 2017
Taxane-based Combination Therapies for Metastatic Prostate CancerPaul G Corn, Neeraj Agarwal, John Charles Araujo, et al.
Journal of the National Cancer Institute|September 16, 2011
Novel therapies for metastatic castrate-resistant prostate cancerFarshid Dayyani, Gary E Gallick, Christopher J Logothetis, et al.
Future Medicinal Chemistry|December 16, 2011
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancerGary E Gallick, Paul G Corn, Amado J Zurita, et al.
European Urology|July 14, 2019
Prostate Cancer: Quo Vadis?Christopher J Logothetis, Ana Aparicio, Filippos Koinis, et al.
Nature Genetics|October 14, 2003
Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau proteinPaul G Corn, E Robert McDonald, James G Herman, et al.
Cancer Biology & Therapy|December 25, 2008
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivityAbujiang Pataer, Stephen G Swisher, Jack A Roth, et al.
Cancer Metastasis Reviews|February 14, 2014
Src signaling pathways in prostate cancerAndreas Varkaris, Anastasia D Katsiampoura, John C Araujo, et al.
Expert Opinion on Investigational Drugs|November 1, 2011
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trialsAndreas Varkaris, Paul G Corn, Sanchaika Gaur, et al.
Current Medicinal Chemistry|December 17, 2016
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future DirectionsSpyridon P Basourakos, Likun Li, Ana M Aparicio, et al.
Pageof 10